Navigation Links
Despite Lucentis's Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
Date:5/29/2013

EXTON, Pa., May 29, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite the approval of Genentech's Lucentis 0.3 mg in August 2012 as the first intravitreal therapy (IVT) for the treatment of diabetic macular edema (DME), Genentech's Avastin continues to dominate the market with 67 percent share of IVT-treated DME patients — similar to the percentage reported in September 2012 — mostly due to Avastin's low cost and broad managed care coverage. Nevertheless, one-third of the 100 U.S. retinal specialists and general ophthalmologists surveyed report a recent decrease in their use of Avastin, owing in part to a preference for Lucentis 0.3 mg.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report entitled TreatmentTrends®: Diabetic Retinopathy/Diabetic Macular Edema (U.S.) 2013 finds that share of Lucentis (all doses) among IVT-treated patients has increased significantly from 14 to 20 percent over the past six months, driven in part by a growing Lucentis prescriber base, which may reflect the importance of the expanded label to physicians' likelihood to prescribe the drug. Separately, Regeneron's Eylea share has also increased slightly, but not significantly, from 5 to 8 percent of IVT-treated DME patients. One-half of surveyed physicians believe that expanded labeling of Eylea to include DME would increase their willingness to prescribe Eylea, thanks mostly to an anticipated positive impact on managed care coverage for DME. However, it is important to note that, even with the expanded Lucentis label, surveyed physicians rate Lucentis 0.3 mg significantly lower than Avastin on managed care coverage and out of pocket cost remains a commonly cited obstacle to Lucentis use.

"With almost three-quarters of surveyed physicians agreeing that cost to the patient plays a large role in their prescribing decision when initiating treatment, managed care coverage and out-of-pocket cost will remain barriers to branded agent uptake as long as compounded Avastin owns the cost benefit proposition in this market," said BioTrends Research Group Ophthalmology Senior Director Virginia Schobel .

Additionally, the report finds that with no products approved for the treatment of diabetic retinopathy (DR), most nonproliferative DR patients still receive systemic control, while the majority of proliferative DR (PDR) patients are treated with scatter laser photocoagulation. Reported treatment patterns suggest that the approval of Lucentis 0.3 mg for DME has not significantly affected the use of IVT therapy for DR or Lucentis share within IVT-treated DR patients. While surveyed physicians anticipate some increase in IVT use among PDR patients over the next six months, a lack of late-stage products suggests that limited changes to the overall DR treatment algorithm are likely to occur during the foreseeable future.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Sales Jobs Rising Despite Challenges Facing the Industry
2. Biotech Executive Salaries Continue to Rise Despite Weak Economy
3. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
4. McGladrey Manufacturing and Distribution Monitor® Shows Business Accelerating Despite Concerns About Government Gridlock
5. Recent Research Questions the Effectiveness of Back Surgery
6. The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be Effective in Dilated Cardiomyopathy
7. Drink to Your (Oral) Health: Atlanta Dentist Looks at Two Recent Studies Exploring Green Tea’s Effects on Oral Health
8. SoundConnect Recently Selected by iCIMS, Inc.
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. Taylor-Wharton™ Announces Recent Appointments in its Global Operations
11. Recent Research Shows Benefits of Chiropractic Care for Infantile Colic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... ... 30, 2019 , ... Object Pharma, Inc., a startup company ... Metabiologics, Inc., a globally recognized leader in the production and sale of botulinum ... a full spectrum of botulinum neurotoxins, as well as a CDC approved facility ...
(Date:5/15/2019)... ... ... Milton Hershey School® has named William Charles Ballough Harding ’78 the 2019 ... he is changing lives by creating solutions to global healthcare challenges through the development ... our founders – Milton and Catherine Hershey – who always hoped for Milton Hershey ...
(Date:5/8/2019)... ... , ... Standing at 16.2 hands, Atlas is on the large side for a Quarter Horse. ... racing, among other activities. When loping around a corner in late 2017, Atlas tripped ... horse to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... standard, REPROCELL USA Inc. has demonstrated its ability to provide various services ... aims to enhance customer satisfaction through the effective implementation of its quality ...
Breaking Biology Technology:
(Date:7/9/2019)... ... July 08, 2019 , ... ... in the biotechnology hub of Cambridge, MA. This expansion strengthens KMK’s presence for ... research , and sales force effectiveness consulting for the biotechnology corridor. ...
(Date:6/27/2019)... IRVINE, Calif. (PRWEB) , ... June 27, 2019 , ... ... from the Illuminating Energy Society (IES), which honored the designers for creating both engaging ... area of 701B Street , an office tower in San Diego, California earned ...
(Date:6/20/2019)... ... 2019 , ... The half-million dollars in Alzheimer’s disease (AD) ... the possibly millions of dollars of “high priority” grants now offered by the ... affirmation” of the need to investigate more thoroughly the possible roles of germs ...
Breaking Biology News(10 mins):